Rotenone, an anticarcinogen, inhibits cellular proliferation but not peroxisome proliferation in mouse liver

Area of Science:

• Toxicology
• Hepatocarcinogenesis
• Cell Proliferation

Background:

• Previous National Toxicology Program (NTP) studies indicated rotenone reduced background hepatocellular carcinoma incidence in male B6C3F1 mice.
• Rotenone's impact on liver cell replication and its interaction with peroxisome proliferators required further investigation.

Purpose of the Study:

• To investigate the effect of rotenone on basal hepatic labeling index and hepatocellular proliferation in male B6C3F1 mice.
• To determine if rotenone inhibits hepatocellular proliferation induced by the peroxisome proliferator Wy-14,643.
• To explore rotenone's potential role in understanding the interplay between cell proliferation, peroxisomal proliferation, and hepatocarcinogenesis.

Main Methods:

• Administration of rotenone to male B6C3F1 mice to assess dose-dependent effects on hepatic labeling index.
• Co-administration of rotenone and Wy-14,643 to evaluate inhibition of induced hepatocellular and peroxisome proliferation.
• Analysis of liver tissues to quantify cell replication and peroxisome proliferation markers.

Main Results:

• Rotenone significantly reduced the basal hepatic labeling index in a dose-dependent manner.
• Rotenone inhibited hepatocellular proliferation induced by Wy-14,643.
• Rotenone did not inhibit peroxisome proliferation induced by Wy-14,643.

Conclusions:

• The reduction in hepatic tumors by rotenone may be attributed to decreased liver cell replication.
• Peroxisome proliferation can occur independently of hepatocellular proliferation.
• Rotenone shows potential as a tool for investigating the relationships between cell proliferation, peroxisomal proliferation, and the development of liver cancer.